Dermatitis - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 381 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dermatitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dermatitis - Pipeline Review, H1 2015’, provides an overview of the Dermatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Dermatitis Overview 7
Therapeutics Development 8
Dermatitis - Therapeutics under Development by Companies 10
Dermatitis - Therapeutics under Investigation by Universities/Institutes 18
Dermatitis - Pipeline Products Glance 19
Dermatitis - Products under Development by Companies 23
Dermatitis - Products under Investigation by Universities/Institutes 32
Dermatitis - Companies Involved in Therapeutics Development 33
Dermatitis - Therapeutics Assessment 120
Drug Profiles 132
Dermatitis - Recent Pipeline Updates 296
Dermatitis - Dormant Projects 344
Dermatitis - Discontinued Products 357
Dermatitis - Product Development Milestones 359
Appendix 365

List of Tables
Number of Products under Development for Dermatitis, H1 2015 23
Number of Products under Development for Dermatitis - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 26
Number of Products under Development by Companies, H1 2015 (Contd..1) 27
Number of Products under Development by Companies, H1 2015 (Contd..2) 28
Number of Products under Development by Companies, H1 2015 (Contd..3) 29
Number of Products under Development by Companies, H1 2015 (Contd..4) 30
Number of Products under Development by Companies, H1 2015 (Contd..5) 31
Number of Products under Development by Companies, H1 2015 (Contd..6) 32
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Development, H1 2015 36
Comparative Analysis by Unknown Stage Development, H1 2015 37
Products under Development by Companies, H1 2015 38
Products under Development by Companies, H1 2015 (Contd..1) 39
Products under Development by Companies, H1 2015 (Contd..2) 40
Products under Development by Companies, H1 2015 (Contd..3) 41
Products under Development by Companies, H1 2015 (Contd..4) 42
Products under Development by Companies, H1 2015 (Contd..5) 43
Products under Development by Companies, H1 2015 (Contd..6) 44
Products under Development by Companies, H1 2015 (Contd..7) 45
Products under Development by Companies, H1 2015 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2015 47
Dermatitis - Pipeline by AlbireoPharma, H1 2015 48
Dermatitis - Pipeline by Amorepacific Corporation, H1 2015 49
Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 50
Dermatitis - Pipeline by AnaMar AB, H1 2015 51
Dermatitis - Pipeline by AnaptysBio, Inc., H1 2015 52
Dermatitis - Pipeline by AnGes MG, Inc., H1 2015 53
Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 54
Dermatitis - Pipeline by arGEN-X BV, H1 2015 55
Dermatitis - Pipeline by Biomar Microbial Technologies, H1 2015 56
Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2015 57
Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2015 58
Dermatitis - Pipeline by Bristol-Myers Squibb Company, H1 2015 59
Dermatitis - Pipeline by Celgene Corporation, H1 2015 60
Dermatitis - Pipeline by Celsus Therapeutics Plc, H1 2015 61
Dermatitis - Pipeline by ChemoCentryx, Inc., H1 2015 62
Dermatitis - Pipeline by China Biologic Products, Inc., H1 2015 63
Dermatitis - Pipeline by ChironWells GmbH, H1 2015 64
Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 65
Dermatitis - Pipeline by Circassia Pharmaceuticals plc, H1 2015 66
Dermatitis - Pipeline by Convoy Therapeutics, Inc., H1 2015 67
Dermatitis - Pipeline by Creabilis SA, H1 2015 68
Dermatitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 69
Dermatitis - Pipeline by Dermira Inc., H1 2015 70
Dermatitis - Pipeline by Eisai Co., Ltd., H1 2015 71
Dermatitis - Pipeline by EpiPharm AG, H1 2015 72
Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 73
Dermatitis - Pipeline by FAES Farma SA, H1 2015 74
Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 75
Dermatitis - Pipeline by Fountain Biopharma Inc., H1 2015 76
Dermatitis - Pipeline by GlaxoSmithKline plc, H1 2015 77
Dermatitis - Pipeline by GlycaNova Norway AS, H1 2015 78
Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 79
Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H1 2015 80
Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 81
Dermatitis - Pipeline by Herantis Pharma plc., H1 2015 82
Dermatitis - Pipeline by IMMD Inc., H1 2015 83
Dermatitis - Pipeline by Immune Response BioPharma, Inc., H1 2015 84
Dermatitis - Pipeline by Inflamalps SA, H1 2015 85
Dermatitis - Pipeline by Janssen Research & Development, LLC, H1 2015 86
Dermatitis - Pipeline by Johnson & Johnson, H1 2015 87
Dermatitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 88
Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2015 89
Dermatitis - Pipeline by LEO Pharma A/S, H1 2015 90
Dermatitis - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 91
Dermatitis - Pipeline by Madam Therapeutics B.V., H1 2015 92
Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2015 93
Dermatitis - Pipeline by Maruho Co., Ltd., H1 2015 94
Dermatitis - Pipeline by MedImmune, LLC, H1 2015 95
Dermatitis - Pipeline by Merck & Co., Inc., H1 2015 96
Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 97
Dermatitis - Pipeline by Nabriva Therapeutics AG, H1 2015 98
Dermatitis - Pipeline by NeoPharm Co., Ltd., H1 2015 99
Dermatitis - Pipeline by Novan, Inc., H1 2015 100
Dermatitis - Pipeline by Novartis AG, H1 2015 101
Dermatitis - Pipeline by Nuvo Research Inc., H1 2015 102
Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 103
Dermatitis - Pipeline by Oxagen Limited, H1 2015 104
Dermatitis - Pipeline by Pergamum AB, H1 2015 105
Dermatitis - Pipeline by Pfizer Inc., H1 2015 106
Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2015 107
Dermatitis - Pipeline by Pharmedartis GmbH, H1 2015 108
Dermatitis - Pipeline by Phosphagenics Limited, H1 2015 109
Dermatitis - Pipeline by ProCertus BioPharm Inc., H1 2015 110
Dermatitis - Pipeline by Promius Pharma, LLC, H1 2015 111
Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 112
Dermatitis - Pipeline by R-Tech Ueno, Ltd., H1 2015 113
Dermatitis - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 114
Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 115
Dermatitis - Pipeline by RestorGenex Corporation, H1 2015 116
Dermatitis - Pipeline by Stemnion, Inc, H1 2015 117
Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 118
Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 119
Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2015 120
Dermatitis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 121
Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 122
Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 123
Dermatitis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 124
Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 125
Dermatitis - Pipeline by Vicore Pharma AB, H1 2015 126
Dermatitis - Pipeline by Vida Therapeutics Inc., H1 2015 127
Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 128
Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 129
Dermatitis - Pipeline by Welichem Biotech Inc., H1 2015 130
Dermatitis - Pipeline by XBiotech USA, Inc., H1 2015 131
Dermatitis - Pipeline by Xencor, Inc., H1 2015 132
Dermatitis - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 133
Dermatitis - Pipeline by Ziarco Pharma Ltd, H1 2015 134
Assessment by Monotherapy Products, H1 2015 135
Number of Products by Stage and Target, H1 2015 137
Number of Products by Stage and Mechanism of Action, H1 2015 141
Number of Products by Stage and Route of Administration, H1 2015 144
Number of Products by Stage and Molecule Type, H1 2015 146
Dermatitis Therapeutics - Recent Pipeline Updates, H1 2015 311
Dermatitis - Dormant Projects, H1 2015 359
Dermatitis - Dormant Projects (Contd..1), H1 2015 360
Dermatitis - Dormant Projects (Contd..2), H1 2015 361
Dermatitis - Dormant Projects (Contd..3), H1 2015 362
Dermatitis - Dormant Projects (Contd..4), H1 2015 363
Dermatitis - Dormant Projects (Contd..5), H1 2015 364
Dermatitis - Dormant Projects (Contd..6), H1 2015 365
Dermatitis - Dormant Projects (Contd..7), H1 2015 366
Dermatitis - Dormant Projects (Contd..8), H1 2015 367
Dermatitis - Dormant Projects (Contd..9), H1 2015 368
Dermatitis - Dormant Projects (Contd..10), H1 2015 369
Dermatitis - Dormant Projects (Contd..11), H1 2015 370
Dermatitis - Dormant Projects (Contd..12), H1 2015 371
Dermatitis - Discontinued Products, H1 2015 372
Dermatitis - Discontinued Products (Contd..1), H1 2015 373